ADAG
Adagene, Inc.
NASDAQ · Healthcare · Biotechnology · CN
$2.42
+2.77%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$2.49
From 52W high−49.48%
Volume61157.00
Market cap$162.15M
P/E (TTM)—
P/S (TTM)17.4x
Div yield—
Key dataNov 4, 2026
Open
$2.49
From 52W high
−49.48%
Volume
61157.00
Market cap
$162.15M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.6x
P/E (TTM)
—
RSI (14)
41.7
MomentumView details →
1D Return
+2.77%
YTD Return
+26.46%
SummaryUpdated Jun 1, 2026
Adagene Inc. (NASDAQ:ADAG) is a clinical-stage biopharmaceutical company founded in 2011 and headquartered in Suzhou, China. The company went public on February 9, 2021, and focuses on developing innovative monoclonal antibody therapies for cancer treatment. Adagene specializes in creating next-generation antibody drugs using proprietary platforms to address limitations of existing cancer immunotherapies. The company operates primarily in the oncology space, developing treatments for both solid tumors and blood cancers.
Similar companies
Latest newsMore news →
Adagene announced that the first patient was dosed in a Phase 1 study evaluating muzastotug in combination with INCYTE CORP's INCA33890 in third-line microsatellite-stable colorectal cancer patients, with and without liver metastases.7d agoChina's National Medical Products Administration approved Adagene's investigational new drug application for ADG138, a double-masked HER2xCD3 bispecific T-cell engager, with a Phase 1 study in advanced solid tumors expected to begin in China in Q4 2026.43d ago